

Keryx Biopharmaceuticals, Inc. and Siegfried enter into a Master Manufacturing Services and Supply Agreement



We like to inform that on December 20, 2017, Keryx Biopharmaceuticals, Inc. and Siegfried entered into a Master Manufacturing Services and Supply Agreement for Siegfried to perform certain manufacturing activities at its manufacturing facilities in Saint Vulbas, France and Pennsville, New Jersey as well as to manufacture and supply GMP-grade quantities of the proprietary active pharmaceutical ingredient for Keryx's drug product, Auryxia.

The Agreement has an initial term ending on December 31, 2021 and will automatically renew after that for successive terms of one year each.

We are delighted about our strengthened partnership with Keryx Biopharmaceuticals, Inc.

Contact

Media:

Peter Gehler
Chief Communications Officer
peter.gehler@siegfried.ch
Tel. +41 62 746 11 48
Mobile +41 79 416 41 16

Business Development:

Marianne Spaene
Global Head Business Development & Sales
marianne.spaene@siegfried.ch
Tel. +41 62 746 15 20

Siegfried Holding AG
Untere Bruehlstrasse 4
CH-4800 Zofingen

About Siegfried

The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, the USA, Malta, China, Germany and France. At the end of 2016, Siegfried reported annual sales of CHF 718 million and employs approximately 2300 employees at nine locations on three continents. Siegfried Holding AG is listed on the Swiss Exchange (SIX: SFZN).

Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediates and controlled substances, and provides development and production services for finished dosage forms including sterile filling.

This News Release on the web

<http://www.siegfried.ch/media-releases/>